Welcome to our dedicated page for Apyx Medical news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical stock.
Apyx Medical Corporation reports news on its surgical aesthetics medical-device business, including products marketed as Renuvion, the AYON Body Contouring System, and J-Plasma. Updates commonly cover FDA 510(k) clearances, body contouring capabilities, controlled-heat tissue applications, commercial activity in cosmetic surgery and hospital surgical markets, and OEM agreements with other medical device manufacturers.
The company’s recurring financial releases discuss revenue by its Surgical Aesthetics and Original Equipment Manufacturing segments, product demand for generators and single-use handpieces, U.S. and international sales trends, and management conference participation.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Apyx Medical Corporation (NASDAQ:APYX) announced that it will release its financial results for Q1 of fiscal year 2023 before the market opens on May 11th. A conference call will follow at 8:00 a.m. Eastern Time on the same day, allowing for a discussion of the results and a Q&A session. Interested callers can join by dialing 877-407-8289 (or 201-689-8341 internationally) with access code 13737575. A live webcast will also be available through the Company’s Investor Relations section. This financial update is anticipated to provide insights into Apyx Medical's performance in the advanced energy technology market, including its innovative products Renuvion and J-Plasma, which are designed for cosmetic and hospital surgical applications.